Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men

The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to...

Full description

Bibliographic Details
Main Authors: Jessica A. Kahn, Marvin Belzer, Xiaofei Chi, Jeannette Lee, Aditya H. Gaur, Kenneth Mayer, Jaime Martinez, Donna C. Futterman, Elizabeth A. Stier, Mary E. Paul, Elizabeth Y. Chiao, Daniel Reirden, Steven E. Goldstone, Ana P. Ortiz Martinez, Edward R. Cachay, Luis F. Barroso, Maria Da Costa, Craig M. Wilson, Joel M. Palefsky
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Papillomavirus Research
Online Access:http://www.sciencedirect.com/science/article/pii/S2405852118300892
id doaj-db58bf2fa98c43f59487e25134c46dd2
record_format Article
spelling doaj-db58bf2fa98c43f59487e25134c46dd22020-11-25T00:37:09ZengElsevierPapillomavirus Research2405-85212019-06-0175261Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with menJessica A. Kahn0Marvin Belzer1Xiaofei Chi2Jeannette Lee3Aditya H. Gaur4Kenneth Mayer5Jaime Martinez6Donna C. Futterman7Elizabeth A. Stier8Mary E. Paul9Elizabeth Y. Chiao10Daniel Reirden11Steven E. Goldstone12Ana P. Ortiz Martinez13Edward R. Cachay14Luis F. Barroso15Maria Da Costa16Craig M. Wilson17Joel M. Palefsky18Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA; Correspondence to: Division of Adolescent Medicine, MLC 4000, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.Department of Pediatrics, University of Southern California, Los Angeles, CA, USADepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USADepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USADepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USAHarvard T.H. Chan School of Public Health, Boston, MA, USAJohn H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USAAlbert Einstein College of Medicine, Bronx, NY, USABoston University School of Medicine, Boston, MA, USABaylor College of Medicine, Houston, TX, USABaylor College of Medicine, Houston, TX, USADepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USAIcahn School of Medicine at Mount Sinai, New York, NY, USACancer Control and Population Sciences Program, University of Puerto Rico, San Juan, PR, USADepartment of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, CA, USADepartment of Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USADepartment of Medicine, University of California San Francisco, San Francisco, CA, USADepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USADepartment of Medicine, University of California San Francisco, San Francisco, CA, USAThe aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. Clinical trial number: NCT01209325 Keywords: Adolescents, Clinical trials, Men who have sex with men, Vaccine, Human papillomavirus, HIVhttp://www.sciencedirect.com/science/article/pii/S2405852118300892
collection DOAJ
language English
format Article
sources DOAJ
author Jessica A. Kahn
Marvin Belzer
Xiaofei Chi
Jeannette Lee
Aditya H. Gaur
Kenneth Mayer
Jaime Martinez
Donna C. Futterman
Elizabeth A. Stier
Mary E. Paul
Elizabeth Y. Chiao
Daniel Reirden
Steven E. Goldstone
Ana P. Ortiz Martinez
Edward R. Cachay
Luis F. Barroso
Maria Da Costa
Craig M. Wilson
Joel M. Palefsky
spellingShingle Jessica A. Kahn
Marvin Belzer
Xiaofei Chi
Jeannette Lee
Aditya H. Gaur
Kenneth Mayer
Jaime Martinez
Donna C. Futterman
Elizabeth A. Stier
Mary E. Paul
Elizabeth Y. Chiao
Daniel Reirden
Steven E. Goldstone
Ana P. Ortiz Martinez
Edward R. Cachay
Luis F. Barroso
Maria Da Costa
Craig M. Wilson
Joel M. Palefsky
Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
Papillomavirus Research
author_facet Jessica A. Kahn
Marvin Belzer
Xiaofei Chi
Jeannette Lee
Aditya H. Gaur
Kenneth Mayer
Jaime Martinez
Donna C. Futterman
Elizabeth A. Stier
Mary E. Paul
Elizabeth Y. Chiao
Daniel Reirden
Steven E. Goldstone
Ana P. Ortiz Martinez
Edward R. Cachay
Luis F. Barroso
Maria Da Costa
Craig M. Wilson
Joel M. Palefsky
author_sort Jessica A. Kahn
title Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
title_short Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
title_full Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
title_fullStr Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
title_full_unstemmed Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
title_sort pre-vaccination prevalence of anogenital and oral human papillomavirus in young hiv-infected men who have sex with men
publisher Elsevier
series Papillomavirus Research
issn 2405-8521
publishDate 2019-06-01
description The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. Clinical trial number: NCT01209325 Keywords: Adolescents, Clinical trials, Men who have sex with men, Vaccine, Human papillomavirus, HIV
url http://www.sciencedirect.com/science/article/pii/S2405852118300892
work_keys_str_mv AT jessicaakahn prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT marvinbelzer prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT xiaofeichi prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT jeannettelee prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT adityahgaur prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT kennethmayer prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT jaimemartinez prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT donnacfutterman prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT elizabethastier prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT maryepaul prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT elizabethychiao prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT danielreirden prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT stevenegoldstone prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT anaportizmartinez prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT edwardrcachay prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT luisfbarroso prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT mariadacosta prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT craigmwilson prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
AT joelmpalefsky prevaccinationprevalenceofanogenitalandoralhumanpapillomavirusinyounghivinfectedmenwhohavesexwithmen
_version_ 1725302275225681920